sapitinib
Small moleculeexperimental
Clinical trial activity
12 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00637039)
Timeline
Indications
Mechanism of action
ERBB3 inhibitor
EGFR inhibitor
ERBB2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1- Mol. weight
- 473.94 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2408045 ↗
Also known as
- azd8931
- azd8931
- azd8931
- azd 8931
- azd-8931
- azd-8931
- azd-8931
- sapitinib
- sapitinib
- sapitinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01862003 | Phase 2 | May 1, 2014 | AstraZeneca, Cancer Research UK, National Institute for Health Research, United Kingdom, University of London |
| NCT02117167 | Phase 2 | Apr 23, 2014 | AstraZeneca, Fondation ARC, Groupe Hospitalier Paris Saint Joseph, Institut Gustave Roussy, UNICANCER |
| NCT02299999 | Phase 2 | Apr 7, 2014 | AstraZeneca, Fondation ARC, Institut Gustave Roussy, UNICANCER |
| NCT01596530 | Phase 1 | Jun 1, 2012 | AstraZeneca |
| NCT01579578 | Phase 2 | Apr 1, 2012 | AstraZeneca, Scarborough General Hospital |
| NCT01330758 | Phase 1 | Apr 1, 2011 | AstraZeneca, IQVIA |
| NCT01284595 | Phase 1 | Mar 1, 2011 | AstraZeneca, IQVIA |
| NCT01151215 | Phase 2 | Jun 1, 2010 | AstraZeneca, Royal Marsden Hospital NHS Trust |
| NCT01003158 | Phase 1 | Oct 1, 2009 | AstraZeneca, Kindai University |
| NCT00900627 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2009 | AstraZeneca, Universidad Autonoma de Barcelona |
| NCT00879346 | Phase 1 | Mar 1, 2009 | AstraZeneca |
| NCT00637039 | Phase 1 | Feb 1, 2008 | AstraZeneca, GU Russian Oncology Research Centre |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 12 | 9 | 2 | 2008 |
| Fondation ARC | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Institut Gustave Roussy | Academic/Hospital | 2 | 0 | 1 | 2014 |
| IQVIA | For profit | 2 | 0 | 1 | 2011 |
| UNICANCER | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Groupe Hospitalier Paris Saint Joseph | Academic/Hospital | 1 | 0 | 1 | 2014 |
| GU Russian Oncology Research Centre | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Kindai University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| National Institute for Health Research, United Kingdom | Government | 1 | 0 | 1 | 2014 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Scarborough General Hospital | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2014 |
14 organizations
Page 1 / 1